Premier Alternatives

Outpace Bio

Discovery Tools (Healthcare) · Seattle, WA · Founded 2020 · Privately Held (backing)

Developer of cell therapies designed to improve the safety and efficacy of gene therapies. Outpace Bio is based in Seattle, WA and was founded in 2020. Its last known valuation is $220 million. It has raised $199 million across 1 recorded round; the latest was a $144 million Series B in Jul 2024.

Last price · $/share
—
Implied valuation
$220.0M
Total raised
$199.0M
Last round
Early Stage VC (Series B)
Jul 2024

Outpace Bio key facts

  • Developer of cell therapies designed to improve the safety and efficacy of gene therapies.
  • Outpace Bio’s last known valuation is $220.0M.
  • It has raised $199.0M across 1 recorded rounds; the latest was Early Stage VC (Series B) ($144.0M) in Jul 2024.
  • Notable investors include Mana Ventures, Gaingels, RA Capital Management, Abstract Ventures, Qiming Venture Partners — 20 tracked in total.
  • Outpace Bio has filed 1 Form D with the SEC, most recently Aug 2024 ($56.0M sold to 25 investors).
  • Status: Privately Held (backing).
Free account
More of Outpace Bio with a free account
  • ·The complete investor list: 20 names
  • ·Watch Outpace Bio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Outpace Bio funding rounds

1 rounds
Jul 2024Early Stage VC (Series B)$144.0M▮
Full funding history →

Outpace Bio valuation

Outpace Bio's last known valuation is $220 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.

How much has Outpace Bio raised?

Outpace Bio has raised $199 million in total; 1 of its rounds is on record. The largest on record was a $144 million Series B in Jul 2024.

Outpace Bio has filed 1 Form D with the SEC, most recently in Aug 2024 ($56 million sold to 25 investors).

Outpace Bio investors

20 investors are on record for Outpace Bio, including Mana Ventures, Gaingels, RA Capital Management and Abstract Ventures. By type, the record holds 5 venture capital firms and 3 asset managers. The Series B in Jul 2024 drew 15 investors.

Comparable companies

Comparable discovery tools (healthcare) names by valuation on PrivateMarketView: Scipher Medicine ($496 million), TRIANA Biomedicines ($258 million) and Nature's Toolbox ($71 million).

About Outpace Bio

Developer of cell therapies designed to improve the safety and efficacy of gene therapies. The company's versatile platform combines the design of biological functions with cellular control modalities, harnessing the complexity of cellular biology to tackle incurable diseases, it uses AI powered protein design to deliver cell therapy for solid tumors by programming cells for improved function inside the patient, enabling companies to collaborate with industry leaders by incorporating insights and creating therapies using protein design and synthetic biology.

Industry
Discovery Tools (Healthcare)
Sector
Healthcare
HQ
Seattle, WA, United States
Founded
2020
Employees
71
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.

Valuation on record
$220.0M

Outpace Bio’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.